澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

RADIOPHARM THERANOSTICS LTD

0.005

0.000

成交量：239.18万

成交额：1.19万

市值：2,355.44万

市盈率：-0.27

高：0.005

开：0.005

低：0.004

收：0.005

52周最高：0.037

52周最低：0.004

股本：47.11亿

流通股本：33.43亿

量比：0.27

换手率：0.07%

股息：- -

股息率：- -

每股收益(TTM):-0.019

每股收益(LYR):-0.019

净资产收益率：-174.71%

总资产收益率：-45.15%

市净率：0.95

市盈率(LYR):-0.27

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Radiopharm Theranostics Ltd 披露：收到澳交所通知，涉嫌违反上市规则10.11

Radiopharm Theranostics：所有可评估胰腺癌患者均观察到显著肿瘤摄取

Radiopharm Theranostics：Rad301受试者安全性良好，生物分布表现积极

Radiopharm Theranostics公布Rad301在胰腺导管腺癌患者中的I期影像试验积极数据

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/RAD.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.005,"timestamp":1791781920000,"preClose":0.005,"halted":0,"volume":2391794,"delay":0,"changeRate":0,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4710883000,"eps":-0.01853,"marketStatus":"未开盘","change":0,"latestTime":"10-12 16:12:00 AEDT","open":0.005,"high":0.005,"low":0.004,"amount":11890,"amplitude":0.2,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.01853,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":0.26626797544462183,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.005,"auctionPrice":0.005,"auctionVolume":3704,"auction":3,"marketStatus":"盘后竞价","timestamp":1791781783455}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-45.15%","roe":"-174.71%","lyrEps":-0.01853,"volumeRatio":0.26626797544462183,"shares":4710883000,"dividePrice":0,"high":0.005,"amplitude":0.2,"preClose":0.005,"low":0.004,"week52Low":0.004,"pbRate":"0.95","psRate":"1.83","week52High":0.037,"institutionHeld":0,"latestPrice":0.005,"eps":-0.01853,"divideRate":0,"volume":2391794,"delay":0,"ttmEps":-0.01853,"open":0.005,"prevYearClose":0.025,"prevWeekClose":0.005,"prevMonthClose":0.006,"prevQuarterClose":0.006,"fiveDayClose":0.006,"twentyDayClose":0.009,"sixtyDayClose":0.02,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1135157540","title":"Radiopharm Theranostics Ltd 披露：收到澳交所通知，涉嫌违反上市规则10.11","url":"https://stock-news.laohu8.com/highlight/detail?id=1135157540","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135157540?lang=zh_cn&edition=fundamental","pubTime":"2026-10-12 09:33","pubTimestamp":1791768788,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics Ltd 对外宣布，该公司已接到澳大利亚证券交易所（ASX）的通知，指出其存在违反上市规则10.11条的情形。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106926898","title":"Radiopharm Theranostics：所有可评估胰腺癌患者均观察到显著肿瘤摄取","url":"https://stock-news.laohu8.com/highlight/detail?id=1106926898","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106926898?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952276,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics传来重磅消息——在其相关研究中，所有可评估的胰腺癌患者均表现出了显著的肿瘤摄取现象。这一发现无疑为胰腺癌诊疗领域投下了一枚震撼弹。据悉，该结果可能为后续更精准的靶向治疗与成像策略奠定关键基础，其临床意义不容小觑。业界普遍关注，这一积极信号能否顺利转化为切实可行的治疗方案，从而惠及广大患者群体。市场对此消息的初步反应亦颇为敏感，投资者正密切观望后续的详细数据披露与监管审批动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124219327","title":"Radiopharm Theranostics：Rad301受试者安全性良好，生物分布表现积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1124219327","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124219327?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952273,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司宣布，其候选药物Rad301在临床试验中展现出令人鼓舞的结果。所有接受该药物剂量给药的研究对象均表现出良好的安全性，同时生物分布数据也呈现有利态势。这一积极进展为公司研发管线注入了新的信心，Rad301作为潜在治疗方案的可行性与耐受性获得了初步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141615521","title":"Radiopharm Theranostics公布Rad301在胰腺导管腺癌患者中的I期影像试验积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1141615521","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141615521?lang=zh_cn&edition=fundamental","pubTime":"2026-09-09 19:02","pubTimestamp":1788951758,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics今日宣布，其候选药物Rad301在针对胰腺导管腺癌患者的I期影像学临床试验中取得了令人振奋的积极结果。这一进展为该公司在肿瘤精准诊断领域的布局注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAD.AU\",params:#limit:6,delay:true,,,undefined,":[]}}